State Board of Administration of Florida Retirement System Acquires 157,212 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

State Board of Administration of Florida Retirement System raised its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) by 386.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 197,917 shares of the biotechnology company’s stock after purchasing an additional 157,212 shares during the quarter. State Board of Administration of Florida Retirement System owned 0.17% of Heron Therapeutics worth $495,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of HRTX. Douglas Lane & Associates LLC bought a new position in Heron Therapeutics during the fourth quarter valued at $25,000. Venturi Wealth Management LLC bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Heron Therapeutics by 51.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,738 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 5,024 shares during the last quarter. Diversified Trust Co bought a new stake in shares of Heron Therapeutics in the 4th quarter worth about $47,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Heron Therapeutics in the 1st quarter worth about $48,000.

Analysts Set New Price Targets

HRTX has been the subject of several analyst reports. Evercore ISI lowered their target price on shares of Heron Therapeutics from $15.00 to $10.00 and set an “outperform” rating for the company in a report on Friday, March 24th. Needham & Company LLC restated a “buy” rating and issued a $7.00 target price on shares of Heron Therapeutics in a report on Friday, April 21st. Finally, StockNews.com initiated coverage on shares of Heron Therapeutics in a report on Thursday. They issued a “hold” rating for the company.

Heron Therapeutics Trading Up 8.3 %

Shares of HRTX opened at $1.30 on Friday. Heron Therapeutics, Inc. has a 1-year low of $1.07 and a 1-year high of $5.62. The company has a 50-day moving average of $2.18 and a 200 day moving average of $2.55. The firm has a market capitalization of $155.62 million, a price-to-earnings ratio of -0.95 and a beta of 0.92. The company has a debt-to-equity ratio of 11.00, a current ratio of 2.29 and a quick ratio of 1.62.

Heron Therapeutics (NASDAQ:HRTX – Get Rating) last announced its quarterly earnings data on Thursday, March 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.08. Heron Therapeutics had a negative net margin of 132.57% and a negative return on equity of 21,127.62%. The company had revenue of $30.00 million during the quarter, compared to analyst estimates of $27.24 million. During the same quarter last year, the business posted ($0.54) EPS. The firm’s revenue for the quarter was up 44.9% on a year-over-year basis. On average, research analysts expect that Heron Therapeutics, Inc. will post -0.9 EPS for the current year.

Heron Therapeutics Company Profile

(Get Rating)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.